• Users Online: 133
  • Print this page
  • Email this page
ORIGINAL ARTICLE
Year : 2019  |  Volume : 8  |  Issue : 2  |  Page : 74-78

Evaluation of hepatitis B vaccination status and immune response among clinicians in a tertiary care hospital in South India


Department of Microbiology, Sri Venkateswara Institute of Medical Sciences, Tirupati, Andhra Pradesh, India

Correspondence Address:
N Ramakrishna
Assistant Professor, Department of Microbiology, Sri Venkateswara Institute of Medical Sciences, Tirupati, Andhra Pradesh
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/JCSR.JCSR_52_19

Rights and Permissions

Background: Hepatitis B virus (HBV) infection remains an important health issue with an estimated 2 billion people worldwide infected with HBV. The risk of contracting HBV by health-care workers (HCWs) is four times greater than that of the general adult population. Protection is defined as immunoglobulin G anti-hepatitis B virus surface antigen antibodies (IgG anti-HBsAbs) level ≥10 mIU/mL following a successful vaccination course. Methods: Three hundred and seventeen clinicians participated in the present study. Vaccination history for hepatitis B was obtained. The concentration of IgG anti-HBsAbs in the serum was determined by quantitative enzyme-linked immunosorbent assay. Results: Two hundred and twenty nine participants (72.2%) had already received a complete course of HBV vaccination, 78 participants (24.6%) had received incomplete course and 10 participants (3%) were non-vaccinated. Among the clinicians having a complete history of vaccination, 86% had protective immunity; while of the 71.7% participants who had incomplete vaccination had protective immunity. We found that four clinicians (1.2%) could not attain protective anti-HBsAb level ≥10 mIU/ml, were designated as non-responders after second vaccine series. Conclusions: Even with full vaccination some of the clinicians have not achieved protective IgG anti-HBsAb titres. Hence, it is imperative that protective antibody titre ≥10 mIU/mL must be maintained in all HCWs. Non-responders must be identified and should be counselled regarding how to prevent hepatitis B infection.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed105    
    Printed0    
    Emailed0    
    PDF Downloaded28    
    Comments [Add]    

Recommend this journal